A Prospective Longitudinal Study to Identify Biomarkers in Children With Hemangiomas
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01598116|
Recruitment Status : Active, not recruiting
First Posted : May 15, 2012
Last Update Posted : March 22, 2018
|Condition or disease||Intervention/treatment|
|Hemangioma||Procedure: Urine collection and ultrasonography Procedure: Urine collection|
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Official Title:||A Prospective Longitudinal Study to Identify Biomarkers in Children With Hemangiomas.|
|Study Start Date :||December 2010|
|Actual Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2018|
Identify biomarkers in children with hemangiomas.
Procedure: Urine collection and ultrasonography
Bagged urine collection and ultrasound at each visit
Age-matched controlled group without hemangioma.
Procedure: Urine collection
Bagged urine collection
- Chemically modified DNA [ Time Frame: 6 months ]Determine whether changes in urinary 8-OHdG can be used as biomarkers for HE growth and involution.
- Blood flow velocity [ Time Frame: 6 months ]Obtain Doppler ultrasound measurements of HE blood flow velocity and size on the same days as serum and urine specimen collection to determine whether changes in blood flow velocity and size correlate with changes in 8-OHdG production.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01598116
|United States, Ohio|
|Nationwide Children's Hospital|
|Columbus, Ohio, United States, 43205|
|Principal Investigator:||Gayle M Gordillo, MD||Ohio State University|